ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för pracinostat. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

21 träffar

Bibliografisk träff 2019-10-18

TGFβ-induced fibroblast activation requires persistent and targeted HDAC-mediated gene repression.

Jones DL, Haak AJ, Caporarello N, Choi KM, Ye Z, Yan H, Varelas X, Ordog T, Ligresti G, Tschumperlin DJ.

J Cell Sci · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1242/jcs.233486

Bibliografisk träff 2019-08-29

A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy.

Yalniz FF, Berdeja JG, Maris MB, Lyons RM, Reeves JA, Essell JH, Patel P, Sekeres M, Hughes A, Mappa S, Garcia-Manero G.

Br J Haematol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1111/bjh.16173

Bibliografisk träff 2019-04-29

Minor structural modifications to Pracinostat produce big changes in its biological responses.

Jia R, Sun P, Zhang Y, Ge Y, Yu N.

Chem Biol Drug Des · research support, non-u.s. gov't; journal article · DOI 10.1111/cbdd.13527

Bibliografisk träff 2019-03-05

HDAC Inhibitors Induce <i>BDNF</i> Expression and Promote Neurite Outgrowth in Human Neural Progenitor Cells-Derived Neurons.

Bagheri A, Habibzadeh P, Razavipour SF, Volmar CH, Chee NT, Brothers SP, Wahlestedt C, Mowla SJ, Faghihi MA.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms20051109

Bibliografisk träff 2019-02-01

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.

Garcia-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, Patnaik M, Odenike O, Sayar H, Tummala M, Patel P, Maness-Harris L, Stuart R, Traer E, Karamlou K, Yacoub A, Ghalie R, Giorgino R, Atallah E.

Blood Adv · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1182/bloodadvances.2018027409

Bibliografisk träff 2019-01-11

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis.

Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S.

Leuk Lymphoma · clinical trial, phase ii; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1080/10428194.2018.1543876

Bibliografisk träff 2019-01-01

Drug Repurposing Screen Identifies Novel Classes of Drugs with Anticancer Activity in Mantle Cell Lymphoma.

Han C, Yu X, Zhang C, Cai Y, Cao Y, Wang S, Shen J.

Comb Chem High Throughput Screen · journal article · DOI 10.2174/1386207322666190916120128

Bibliografisk träff 2018-09-04

<i>Crebbp</i> Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition.

Jia D, Augert A, Kim DW, Eastwood E, Wu N, Ibrahim AH, Kim KB, Dunn CT, Pillai SPS, Gazdar AF, Bolouri H, Park KS, MacPherson D.

Cancer Discov · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/2159-8290.cd-18-0385

Bibliografisk träff 2017-08-25

Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.

Abaza YM, Kadia TM, Jabbour EJ, Konopleva MY, Borthakur G, Ferrajoli A, Estrov Z, Wierda WG, Alfonso A, Chong TH, Chuah C, Koh LP, Goh BC, Chang JE, Durkes DE, Foudray MC, Kantarjian HM, Dong XQ, Garcia-Manero G.

Cancer · comparative study; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1002/cncr.30949

Bibliografisk träff 2017-03-16

The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia.

Rauzan M, Chuah CT, Ko TK, Ong ST.

PLoS One · research-article; journal article · DOI 10.1371/journal.pone.0174107

Bibliografisk träff 2017-01-17

Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.

Garcia-Manero G, Montalban-Bravo G, Berdeja JG, Abaza Y, Jabbour E, Essell J, Lyons RM, Ravandi F, Maris M, Heller B, DeZern AE, Babu S, Wright D, Anz B, Boccia R, Komrokji RS, Kuriakose P, Reeves J, Sekeres MA, Kantarjian HM, Ghalie R, Roboz GJ.

Cancer · clinical trial, phase ii; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1002/cncr.30533

Bibliografisk träff 2016-11-14

Therapeutic activity of the histone deacetylase inhibitor SB939 on renal fibrosis.

Kang SW, Lee SM, Kim JY, Kim SY, Kim YH, Kim TH, Kang MS, Jang WH, Seo SK.

Int Immunopharmacol · journal article · DOI 10.1016/j.intimp.2016.11.008

Bibliografisk träff 2016-04-25

Activating Transcription Factor 3 Expression as a Marker of Response to the Histone Deacetylase Inhibitor Pracinostat.

Sooraj D, Xu D, Cain JE, Gold DP, Williams BR, Williams BR.

Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-15-0890

Bibliografisk träff 2016-02-05

Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.

Ganai SA.

Pharm Biol · review; journal article · DOI 10.3109/13880209.2015.1135966

Bibliografisk träff 2015-05-19

A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.

Eigl BJ, North S, Winquist E, Finch D, Wood L, Sridhar SS, Powers J, Good J, Sharma M, Squire JA, Bazov J, Jamaspishvili T, Cox ME, Bradbury PA, Eisenhauer EA, Chi KN.

Invest New Drugs · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1007/s10637-015-0252-4

Bibliografisk träff 2015-01-28

A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†.

Chu QS, Nielsen TO, Alcindor T, Gupta A, Endo M, Goytain A, Xu H, Verma S, Tozer R, Knowling M, Bramwell VB, Powers J, Seymour LK, Eisenhauer EA.

Ann Oncol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1093/annonc/mdv033

Bibliografisk träff 2013-07-25

A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium.

Zorzi AP, Bernstein M, Samson Y, Wall DA, Desai S, Nicksy D, Wainman N, Eisenhauer E, Baruchel S.

Pediatr Blood Cancer · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1002/pbc.24694

Bibliografisk träff 2013-04-04

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells.

Okabe S, Tauchi T, Tanaka Y, Kimura S, Maekawa T, Ohyashiki K.

Cancer Cell Int · research-article; journal article · DOI 10.1186/1475-2867-13-32

Bibliografisk träff 2012-04-16

Antimalarial activity of the anticancer histone deacetylase inhibitor SB939.

Sumanadasa SD, Goodman CD, Lucke AJ, Skinner-Adams T, Sahama I, Haque A, Do TA, McFadden GI, Fairlie DP, Andrews KT.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.00030-12

Bibliografisk träff 2012-04-02

Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis.

Quintás-Cardama A, Kantarjian H, Estrov Z, Borthakur G, Cortes J, Verstovsek S.

Leuk Res · clinical trial, phase ii; research-article; journal article · DOI 10.1016/j.leukres.2012.03.003

Bibliografisk träff 2011-08-26

Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics.

Jayaraman R, Pilla Reddy V, Pasha MK, Wang H, Sangthongpitag K, Yeo P, Hu CY, Wu X, Xin L, Goh E, New LS, Ethirajulu K.

Drug Metab Dispos · journal article · DOI 10.1124/dmd.111.041558